Subcutaneous IVIG now available

January 16, 2006

ZLB Behring has received FDA approval for the first subcutaneous immunoglobulin, Vivaglobin (Immune Globulin Subcutaneous [Human]), indicated for the treatment of patients with primary immunodeficiency. According to the company, patients can safely self-administer the immunoglobulin and the drug may be appropriate for those who cannot tolerate the intravenous products due to poor venous access or side effects. Portable pumps can be used by the patient to deliver their weekly doses.